Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomaglumetad in clinical high risk for psychosis
NCT03321617Phase 1Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pomaglumetad methionil in psychosis (4 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14. Started Apr 2018; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT03321617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321617.